SSY Group (HK:2005) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Cycloserine Capsules and Lornoxicam for injection. Cycloserine Capsules are aimed at treating tuberculosis and urinary tract infections, while Lornoxicam injections target acute pain management. These approvals mark a significant step in SSY Group’s product development strategy.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
